MedTrace Logo

Treatment of Cerebral Radiation Necrosis With GM1, a Prospective Study

NCT01884987 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2014-01-07

No results posted yet for this study

Summary

Cerebral radiation necrosis (CRN) is a well-documented late complication of radiation therapy for cancers, and may have a devastating effect on the patient's quality of life (QOL). However,CRN was once regarded as a progressive and irreversible disease, no standard therapy has been suggested for CRN. In our clinical practice, we have used monosialotetrahexosylganglioside (GM1)to treat CRN, and found that GM1 can successfully reverse CRN. So we carried out this prospective study to test the efficacy of GM1 for CRN.

Conditions

  • Radiotherapy
  • Nasopharyngeal Carcinoma
  • Cerebral Radiation Necrosis
  • MRI

Interventions

DRUG

GM1

This group will be treated with GM1 80mg daily for 14 days, and then followed with GM1 40mg daily for 46 days.

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • ChaoSu Hu, MD, PhD · Fudan University

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01884987 on ClinicalTrials.gov